Elpiscience (Suzhou) Biopharma, Ltd.

Quick facts

Phase 2 pipeline

• ES014 · Oncology
  ES014 is a monoclonal antibody targeting PD-1.

Phase 1 pipeline

• ES104

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Elpiscience (Suzhou) Biopharma, Ltd. portfolio CI brief
• Elpiscience (Suzhou) Biopharma, Ltd. pipeline updates RSS